# US 2024/0408236 A1 · Method of modulating pcsk9 and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0408236 A1
- Document ID: US20240408236A1
- Status: Published application
- Kind: A1
- Application number: 18/712,079
- Filed: 2022-11-25
- Published: 2024-12-12
- Earliest claimed: 2021-11-26
- Applicants: Epigenic Therapeutics, Inc.
- Inventors: Changyang ZHOU; Yidi SUN; Wenbo PENG; Shaoshuai MAO
- Web page: https://patentgrep.com/patent/US20240408236A1

## CPC

- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- A61K 38/45: Transferases (2)
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C12N 9/1007: {Methyltransferases (general) (2.1.1.)}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 9/6424: {Serine endopeptidases (3.4.21)}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 15/907: {in mammalian cells}
- C12Y 201/01037: DNA (cytosine-5-)-methyltransferase (2.1.1.37)
- C12Y 201/01072: Site-specific DNA-methyltransferase (adenine-specific) (2.1.1.72)
- C12Y 201/01113: Site-specific DNA-methyltransferase (cytosine-N4-specific) (2.1.1.113)
- C12Y 304/21: Serine endopeptidases (3.4.21)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/71: containing domain for transcriptional activaation, e.g. VP16
- C07K 2319/81: containing a Zn-finger domain for DNA binding
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

This disclosure provides CRISPR/Cas9 based fusion molecules and guide RNAs for use in in vivo targeted reduction or elimination of PCSK9 gene products. This disclosure also relates to formulations, methods of production and methods of use thereof.

## Claims

### Claim 1

A method for
(a) reducing or eliminating the expression of a Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) gene product in a cell comprising the step of introducing into the cell:
a fusion molecule comprising a least one DNA binding protein and at least one modulator of gene expression, or a nucleic acid sequence encoding the fusion molecule,
wherein the modulator of gene expression provides a modification of at least one nucleotide near the PCSK9 gene and/or within a PCSK9 regulatory element,
thereby reducing or eliminating the expression of the PCSK9 gene product in the cell; or
(b) expanding a population of cells with a reduced expression of a PCSK9 gene product comprising the steps of:
i) introducing into a plurality of cells a fusion molecule comprising a least one DNA binding protein and at least one modulator of gene expression, or a nucleic acid sequence encoding the fusion molecule,
wherein the modulator of gene expression provides a modification of at least one nucleotide near the PCSK9 gene and/or within a PCSK9 regulatory element,
ii) expanding the plurality of cells to produce a plurality of modified cells that have a reduced expression of the PCSK9 gene product,
wherein the plurality of modified cells has at least 50%, at least 60%, at least 70%, at least 80% or at least 90% reduction in the PCSK9 gene product expression relative to a cell that has not been introduced with the fusion molecule or the nucleic acid sequence, and
wherein the cell is a liver cell: or
(c) (i) treating or alleviating a symptom of a PCSK9 related disorder in a subject or (ii) reducing low density lipoprotein (LDL) cholesterol in a subject, the method comprising the step of introducing to a cell of the subject;
a fusion molecule comprising a least one DNA binding protein and at least one modulator of gene expression, or a nucleic acid sequence encoding the fusion molecule,
wherein the modulator of gene expression provides a modification of at least one nucleotide near the PCSK9 gene and/or within a PCSK9 regulatory element,
thereby treating or alleviating a symptom of a PCSK9 related disorder in the subject.

### Claim at position 2

-5. (canceled)

### Claim 6 (depends on 1)

The method of claim 1, wherein the PCSK9 regulatory element is a core promoter, a proximal promoter, a distal enhancer, a silencer, an insulator element, a boundary element or a locus control region.

### Claim 7 (depends on 1)

The method of claim 1, wherein the modification of at least one nucleotide is a DNA methylation.

### Claim 8 (depends on 1)

The method of claim 1, wherein the at least one modulator of gene expression comprises a DNA methyltransferase (DNMT), a DNA demethylase, a histone methyltransferase, a histone demethylase, or a portion thereof.

### Claim 9 (depends on 8)

The method of claim 8, wherein the DNMT is (a) DNMT3A comprising the amino acid sequence of SEQ ID NO: 23 or (b) DNMT3L comprising the amino acid sequence of SEQ ID NO: 24.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The method of claim 1, wherein the at least one modulator of gene expression comprises a zinc finger protein-based transcription factor or a portion thereof, optionally wherein the zinc finger protein-based transcription factor is Kruppel-associated suppression box (KRAB): optionally wherein the KRAB comprises the amino acid sequence of SEQ ID NO: 22.

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14 (depends on 1)

The method of claim 1, wherein the at least one modulator of gene expression comprises a DNA methyltransferase or a portion thereof and a zinc finger protein-based transcription factor or a portion thereof, optionally wherein the DNA methyltransferase is selected from DNMT3A and DNMT3L and a combination thereof, and the zinc finger protein-based transcription factor is KRAB.

### Claim 15

(canceled)

### Claim 16 (depends on 1)

The method of claim 1, wherein the at least one DNA binding protein is a Cas9, dCas9, Cpf1, a zinc finger nuclease (ZNF), a transcription activator-like effector nuclease (TALEN), a homing endonuclease, a dCas9-FokI nuclease or a MegaTal nuclease optionally wherein the at least one DNA binding protein is dCas9; optionally wherein the dCas9 comprises the amino acid sequence of SEQ ID NO: 1.

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19 (depends on 1)

The method of claim 1, wherein the fusion molecule comprises a dCas9 fused with a KRAB on the C-terminal end and a DNMT3A and a DNMT3L on the N-terminal end optionally wherein the fusion molecule comprises the amino acid sequence of SEQ ID NO: 97.

### Claim 20

(canceled)

### Claim 21 (depends on 1)

The method of claim 1, further comprising the step of introducing at least one single guide RNA (sgRNA) that is complementary to a DNA sequence near the PCSK9 gene and/or within a PCSK9 regulatory element, thereby targeting the fusion molecule to the PCSK9 gene or PCSK9 regulatory element, or a DNA encoding the sgRNA, optionally wherein the sgRNA comprises the nucleic acid sequence of SEQ ID NOS: 27-95 or 98-108.

### Claim 22

(canceled)

### Claim 23

A sgRNA comprising the nucleic acid sequence of any one of SEQ ID NOs: 27-95 or 98-108.

### Claim 24 (depends on 23)

A DNA sequence encoding the sgRNA of claim 23.

### Claim 25

A pharmaceutical composition comprising a fusion molecule comprising a least one DNA binding protein and at least one modulator of gene expression, or a nucleic acid sequence encoding the fusion molecule,
wherein the fusion molecule is targeted to a genomic region near a PCSK9 gene and/or within a PCSK9 regulatory element,
wherein the at least one modulator of gene expression provides a modification of at least one nucleotide near the PCSK9 gene and/or within a PCSK9 regulatory element,
wherein the at least one modulator of gene expression comprises a DNA methyltransferase (DNMT), a DNA demethylase, a histone methyltransferase, a histone demethylase, or a portion thereof, or a zinc finger protein-based transcription factor or a portion thereof, or a combination thereof, and
wherein the at least one DNA binding protein is a Cas9, dCas9, Cpf1, a zinc finger nuclease (ZNF), a transcription activator-like effector nuclease (TALEN), a homing endonuclease, a dCas9-FokI nuclease or a MegaTal nuclease.

### Claim 26 (depends on 25)

The pharmaceutical composition of claim 25, wherein the PCSK9 regulatory element is a transcription start site, core promoter, a proximal promoter, a distal enhancer, a silencer, an insulator element, a boundary element or a locus control region.

### Claim 27

(canceled)

### Claim 28 (depends on 25)

The pharmaceutical composition of claim 25, wherein the at least one modulator of gene expression comprises a DNA methyltransferase (DNMT) or a portion thereof, optionally wherein the DNMT is (a) DNMT3A comprising the amino acid sequence of SEQ ID NO: 23 or (b) DNMT3L comprising the amino acid sequence of SEQ ID NO: 24.

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31 (depends on 25)

The pharmaceutical composition of claim 25, wherein the at least one modulator of gene expression comprises a zinc-finger protein-based transcription factor or a portion thereof, optionally wherein the zinc finger protein-based transcription factor is Kruppel-associated suppression box (KRAB), optionally wherein the KRAB comprises the amino acid sequence of SEQ ID NO: 22.

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34 (depends on 25)

The pharmaceutical composition of claim 25, wherein the at least one modulator of gene expression comprises a DNA methyltransferase or a portion thereof and a zinc finger protein-based transcription factor or a portion thereof, optionally wherein the DNA methyltransferase is selected from DNMT3A and DNMT3L and a combination thereof, and the zinc finger protein-based transcription factor is KRAB.

### Claim 35

(canceled)

### Claim 36 (depends on 25)

The pharmaceutical composition of claim 25, wherein the at least one DNA binding protein is a Cas9, dCas9, Cpf1, a zinc finger nuclease (ZNF), a transcription activator-like effector nuclease (TALEN), a homing endonuclease, a dCas9-FokI nuclease or a MegaTal nuclease optionally wherein the at least one DNA binding protein is dCas9, optionally wherein the dCas9 comprises the amino acid sequence of SEQ ID NO: 1.

### Claim 37

(canceled)

### Claim 38

(canceled)

### Claim 39 (depends on 25)

The pharmaceutical composition of claim 25, wherein the fusion molecule comprises a dCas9 fused with a KRAB on the C-terminal end and a DNMT3A and a DNMT3L on the N-terminal end optionally wherein the fusion molecule comprises the amino acid sequence of SEQ ID NO: 97.

### Claim 40

(canceled)

### Claim 41 (depends on 25)

The pharmaceutical composition of claim 25, further comprising at least one single guide RNA (sgRNA) that is complementary to a DNA sequence near the PCSK9 gene and/or within a PCSK9 regulatory element, optionally wherein the sgRNA comprises the nucleic acid sequence of SEQ ID NOS: 27-95 or 98-108.

### Claim 42

(canceled)
